An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2008 New trial record.